Abstract
Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Graphical Abstract
Current Drug Safety
Title:Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum
Volume: 12 Issue: 2
Author(s): Upinder Kaur, Sankha Shubhra Chakrabarti, Rohit Singh and Indrajeet Singh Gambhir*
Affiliation:
- Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 221005, UP,India
Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Abstract: Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Export Options
About this article
Cite this article as:
Kaur Upinder, Chakrabarti Shubhra Sankha, Singh Rohit and Gambhir Singh Indrajeet*, Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170518153225
DOI https://dx.doi.org/10.2174/1574886312666170518153225 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Current Drug Targets Dermatologic Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis
Mini-Reviews in Medicinal Chemistry COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact
Current Pharmaceutical Design Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety Advanced Protein Drugs and Formulations
Current Protein & Peptide Science Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention
Current Cardiology Reviews Fondaparinux
Current Pharmaceutical Design A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention
Current Signal Transduction Therapy New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
Current Cancer Drug Targets From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology